Underprescription of Step III Opioids in French Cancer Survivors With Chronic Pain: A Call for Integrated Early Palliative Care in Oncology

Asmaa Janah, Anne-Déborah Bouhnik, Rajae Touzani, Marc Karim Bendiane, Patrick Peretti-Watel

▶ To cite this version:

1   # Under-prescription of Step III opioids in French cancer survivors

2   # with chronic pain: a call for integrated early palliative care in

3   # oncology

4   Running title: opioids prescription in survivors with chronic pain

5   Asmaa JANAH[1], Anne-Déborah BOUHNIK[1], Rajae TOUZANI[1,2], Marc-Karim BENDIANE[1], Patrick

6   PERETTI-WATEL[3,4,5]

7   [1] Aix Marseille Univ, INSERM, IRD, SESSTIM, Economics and Social Sciences Applied to Health &

8   Analysis of Medical Information, Marseille, France

9   [2] Institut Paoli Calmettes, SESSTIM, Marseille, France

10   [3] Aix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France

11   [4] IHU-Méditerranée Infection, Marseille, France.

12   [5] ORS PACA, Southeastern Health Regional Observatory, Marseille, France.

1

Abstract

14 **_Context:_** Chronic pain (CP) is a major concern in cancer survivors. Often underreported by

15 patients, it is both under-assessed and undertreated by care providers.

16 **_Objectives:_** To assess CP prevalence and related treatment in cancer survivors five years after

17 diagnosis; to identify factors associated with prescribing opioids among survivors with CP,

18 focusing on access to palliative care (PC).

19 **_Methods_**: In 2015-2016, we interviewed 4,174 French patients diagnosed with cancer five years

20 previously. Combining patient and clinical reported outcomes together with medico-

21 administrative data, we studied factors associated with Step II and Step III opioid prescription in

22 cancer survivors with CP. We performed multinomial logistic regression adjusting for various

23 covariates, including self-reported health status variables and inpatient PC.

24 **_Results:_** Five years after cancer diagnosis, 63.5% of the respondents reported current chronic

25 pain (CP) (i.e., pain ≥ 3 months). Of these, 64.6% and 14.4% were prescribed at least one Step II

26 or Step III opioid, respectively. Only 1.9% had had inpatient PC since diagnosis. After

27 adjustment for age, gender, clinical and self-reported variables, we found that the latter were

28 more likely to receive Step III opioids (adjusted Relative Risk ratio: 5.33; 95% CI: 1.15, 24.58).

29 **_Conclusions:_** This study showed a high prevalence of CP five years after cancer diagnosis. Step

30 III opioids were underprescribed but positively associated with inpatient PC. PC access in France

31 remains limited, especially among cancer survivors. Integrating PC in oncology is essential to

32 provide the best cancer-related symptoms management.

33 **_Keys messages_**: This article provides chronic pain prevalence and its related treatment among

34 survivors, five years after a diagnosis. The findings show high prevalence rate of this symptom

2

35   and its association with other symptoms such as depression and poorer QOL, thus requiring

36   multidisciplinary care such as that offered by palliative care.

37

Introduction

Pain is one of the most common cancer symptoms (1–8). Rarely occurring alone, it is mostly associated with fatigue, depression, anxiety and sleep disorders (9–12). Chronic pain, defined as persistent pain lasting longer than three months (13), is common among cancer survivors and may greatly impair their well-being and quality of life (QOL) (14–16). This type of pain may precede cancer diagnosis, may be caused by ongoing active disease, may be induced by anticancer treatments and procedures, or may be caused by cancer sequelae or its treatment (17,18).

The treatment of pain is a principal component of supportive care that should continue beyond the initial treatment of a disease (19,20). It includes psychological and social support, symptom management and palliative care (PC). The latter offers a patient-centered holistic approach and aims to ensure comfort and the best possible QOL, physically, psychologically, spiritually and socially (21). It takes into account patients' and relatives' specific needs, irrespective of age, of disease type and stage (22–26). Contrary to popular belief, PC could be integrated earlier in conjunction with curative treatment. Early PC access PC can reduce the occurrence of symptoms, including pain. One study reported that early access was associated with a 31% reduction in the risk of severe cancer pain (27).

Current guidelines and gold standards for cancer pain management, established by the World Health Organization (WHO) (28), comprise an analgesic three-step "ladder": non-opioid analgesics (Step I) for mild pain, weak opioids (Step II) for moderate pain, and strong opioids (Step III) for intense pain. Other drugs called adjuvant analgesics can be added when clinically required at any stage of the WHO ladder (29,30). Studies show that properly using this ladder should lead to effective pain relief for the majority of cancer patients at all disease stages

4

(31,32). Other updated versions of this ladder have been found in the literature. On the one hand, some authors have proposed the abolition of the WHO ladder' step II (weak opioids) in favor of the introduction of low doses of step III opioids (33). On the other hand, other authors have proposed a fourth step comprising interventional strategies intended to manage intense to very intense pain (i.e. nerve blocks, spinal administration of local anesthetics and opioids.) (34).

Despite several guidelines for cancer pain management, including those of the WHO (28,35,36), undertreatment is well documented and may concern up to 40% of patients (3,32,37–41). Undertreatment of pain may be explained by under-reporting by patients and under-assessment by doctors. Barriers to reporting include beliefs and meanings that each patient assigns to the experienced pain, together with his/her reluctance to initiate opioids (step III opioids especially) and PC more generally (25,42). The latter reason can also be attributed to care providers.

Given the complexity of pain in people diagnosed with cancer, in particular chronic pain (CP), its frequent association with other symptoms and its impact on QOL, pain management and the relief of psychological, social and spiritual suffering - as described in the concept of "total pain" (43) - could be enhanced by introducing PC early in the disease trajectory.

In France, little is known about the prevalence of chronic pain and its treatment five years after a cancer diagnosis. Accordingly, the aim of this study, using data from the French national survey VICAN (VIe après le CANcer) (44), was to: i) provide the prevalence of CP and related treatment in cancer survivors, five years after diagnosis, ii) study factors associated with opioid prescription in survivors with CP, with a specific focus on the impact of inpatient PC.

Methods

Study design: The VICAN survey

The VICAN survey assessed factors that may adversely affect or enhance the QOL of cancer survivors 2 and 5 years after diagnosis. The survey included adult survivors with primo-cancer diagnosed between January 2010 and December 2011, aged between 18 and 82 years old at diagnosis, still alive 5 years later, and insured under one of France's three main health insurance schemes. The survey was restricted to 12 primo-cancer sites, accounting for 88% of global cancer incidence in France in 2012: breast, lung, colorectal, prostate, upper aerodigestive tract, bladder, kidney, cervical, endometrial, thyroid, Non-Hodgkin lymphoma, and melanoma. A detailed description of the methodology and data collection were published elsewhere (44).

Data were collected from telephone interviews with patients, 2 and 5 years after diagnosis. The first questionnaire (VICAN 2) was administered in 2012 to 4,347 cancer survivors. The second questionnaire (VICAN 5) was administered in 2015 and 2016 to 4,174 individuals. The latter sample included 2,009 individuals who answered VICAN 2 in 2012 (attrition rate of approximately 54%).

The study methodology was approved by the following national ethics commissions: the CCTIRS (Consultative Committee on the Treatment of Health-related data, study registered under no. 11-143), the ISP (Institute of Public Health, study registered under no C11-63) and authorized by the CNIL (French Commission on Individual Data Protection and Public Liberties, study registered under no. 911290). With regard to personal responses and information provided, confidentiality was ensured through data anonymization.

Data sources

Patient questionnaires were complemented by medico-administrative data collected from the French national health insurance databases (Système National l'Information Interrégimes de l'Assurance Maladie, SNIIRAM). Patient questionnaires covered several areas such as socio-demographic and socio-economic status, treatments received and perceived adverse sequalae. Finally, data on routine medical prescriptions and hospital records were collected from the SNIIRAM.

Study population

Overall, 4,174 individuals participated in VICAN 5. For the present work, the study population was limited to respondents who answered questions concerning pain and for whom medico-administrative data were available (i.e. N=4,093).

Indicator measures

Pain measures

In the VICAN 5 survey, recent pain experience was assessed using a panel of questions including validated tool for neuropathic pain screening. Pain assessment combined both subjective (self-reported pain) and objective (SNIIRAM) data. The questionnaire included items on: 1) pain experience (during the previous two weeks, (i.e. yes or no)), 2) its intensity (extremely intense, very intense, quite intense, neither moderate nor intense, quite moderate, very moderate and extremely moderate), and its impact on daily activity (the question being phrased so as to measure respondents' level of agreement that it had in fact an impact: "completely agree", "mostly agree", "do not agree or disagree" , "mostly disagree" "completely disagree"). To screen for CP, respondents who self-reported pain during the previous two weeks were asked how long they had been in pain (<3 months, ≥ 3 months but < 6 months, and ≥ 6 months). The

7

126   usual 3-month threshold was used to define chronic pain (45). Neuropathic pain was assessed

127   using the validated seven-item format of the French DN4 questionnaire (46). Other questions

128   dealt with the use of non-conventional medicine such as acupuncture and hypnosis.

129   ***Opioids and adjuvant analgesics***

130   For each respondent, we retrieved SNIIRAM data on dispensed drugs in community pharmacies

131   from January 2009 to December 2016 using the Anatomical Therapeutic Chemical (ATC)

132   Classification (47) as follows:

133   -   Step II opioids: codeine (ATC: N02AA59, N02AA79), dextropropoxyphene (ATC:

134   N02AC04, N02AC54, N02AC74), and tramadol (ATC: N02AX02, N02AX52).

135   -   Step III opioids: morphine (ATC: N02AA01), fentanyl (ATC: N02AB03), oxycodone (ATC:

136   N02AA55, N02AA05), buprenorphine (ATC: N02AE01), and nalbuphine (ATC: N02AF02).

137   -   Psychotropic drugs: Anxiolytics (ATC: N05B), hypnotics (ATC: N05CD, N05CF, and

138   NO5CX), and antipsychotics (ATC: N05A).

139   These data allowed us to construct binary variables for annual prescriptions of each drug

140   category (Step II opioids, Step III opioids, psychotropic drugs). Another variable combining

141   prescription of Step II and Step III opioids for each year and for the period between diagnosis

142   and the survey (i.e., "no opioid prescription", "Step II opioid prescription", and "Step III opioid

143   prescription") was also created. It constituted our dependent variable.

144   ***Other measurements***

145   In addition to pain, the patient questionnaire evaluated QOL using the SF-12 (48), and anxiety

146   and depression using the HAD scale (49). Cancer-related fatigue was assessed from a score

147   between 0 and 100 evaluated using three items from the EORTC QLQ scale (50). A threshold

148   score of 40 defined a clinically significant (51). An individual comorbidity score was calculated

8

149 from the weighted average of chronic diseases identified over a period of one year (52). Cancer

150 treatment information between 2009 and 2016 (chemotherapy, radiotherapy), in addition to

151 information on metastases, was extracted from the SNIIRAM. We also used the medical

152 information system program (Programme de Médicalisation des Systèmes d'Information, PMSI)

153 database to extract information on hospital stays for PC. More specifically, inpatient PC stays

154 were identified using the ICD-10 PC code (Z.515) as primary diagnosis or related diagnosis.

155 Finally, occupational status was assessed with a ternary variable (Tradesperson/Employee,

156 supervisor and unemployed), which was created *ex post* from job characteristics reported in the

157 questionnaire.

158 Analyses

159 *Weighting method*

160 Weighting coefficients were calculated and applied to ensure the sample was representative of

161 the whole target population (i.e., French adults diagnosed with cancer (for the 12 cancer sites

162 studied) in 2010/2011, insured in one of the three main French health insurance schemes and

163 alive 5 years after diagnosis). Weights were constructed such that the sample structure for

164 these characteristics was comparable to that observed in the sampling frame (44,53).

165 *Statistical analyses*

166 Data were summarized using percentages for categorical variables and means (SD) for

167 continuous variables. First, we compared the distribution of respondents' sociodemographic

168 and medical characteristics between those with and without CP. Second, we limited the

169 analysis to survivors with CP in order to study variables associated with opioid prescription for

170 CP since diagnosis. Chi-squared tests, and *t* tests were used in univariate analyses. To identify

171 factors independently associated with opioid prescription since diagnosis (differentiating Step II

9

172 from Step III opioids), we performed multinomial logistic regression, adjusting for self-reported

173 health status variables at the time of the survey, and for inpatient PC. All analyses were

174 performed using STATA version 12 (STATA Corp, College Station, TX).

175 Results

176 Baseline characteristics

177 Of the 4,174 cancer survivors surveyed in VICAN 5, 4,093 (98.3%) answered questions

178 concerning pain. Among the latter, 39.5% were aged 18-49 at diagnosis and 62.6% were

179 women. Breast cancer accounted for almost half of our sample, while cervical and endometrial

180 cancers were the least frequent.

181 Prevalence and variables associated with CP - Univariate analyses

182 The majority of survivors (73.4%) reported having experienced pain of some type during the

183 previous two weeks. In 86.5% of cases, pain was chronic (i.e., ≥ 3 months). Overall, CP

184 prevalence was 63.5% in our entire study population, ranging from 50.1 to 72.1% for bladder

185 and breast cancer, respectively (Table 1).

186 CP was significantly more frequent in women diagnosed with breast cancer, in younger

187 respondents, in those with a low education level and in those with neuropathic pain.

188 Respondents who reported a clinically significant level of anxiety, depression and/or fatigue,

189 those with a poorer physical and mental quality of life, and those with increased comorbidities

190 were all more likely to experience CP (Table 1).

191 Variables associated with opioid prescription in cancer survivors with CP - Univariate

192 analyses

193 Given the high prevalence of CP in respondents with other symptoms such as anxiety,

194 depression and fatigue, and the significant need for PC in patients with CP compared with the

10

195 rest of the study population, we decided to limit the analyses to cancer survivors with CP, in

196 order to investigate the relationship between opioid prescription in survivors with CP and PC

197 access since diagnosis.

198 Among the 2,578 respondents with CP, 68.1% were women and nearly 41.7% were aged 18-49

199 years old. Moreover, one cancer survivor with CP in four reported having experienced intense

200 pain in the last 15 days preceding the survey and only 1.9% had had inpatient PC at least once

201 since diagnosis (Table 2, 2nd column) .A description of this sub-sample is provided in Table 2

202 where three specific groups are described. In the first group, 21.0% had no opioid prescription

203 since diagnosis. The second group (64.6%) has been prescribed at least one Step II opioid since

204 diagnosis (i.e. exclusively Step II opioid), while the third group (14.4%) has been prescribed at

205 least one Step III opioid since diagnosis (4.2% in survey year).

206 When comparing the second and third groups consecutively with the first group 1 (Table 2), we

207 found in both cases that opioid prescription was more frequent in respondents with

208 neuropathic pain, in those reporting depression, fatigue, and in those with lower scores of

209 physical and mental QOL. In addition, survivors who have experienced moderate pain in the last

210 15 days preceding the survey were more likely to be prescribed step II opioids, while those who

211 have experienced intense pain were more likely to be prescribed step III opioids. Moreover, in

212 both cases, survivors who underwent chemotherapy more frequently and those who had been

213 prescribed psychotropic drugs were more likely to be prescribed opioids. With respect to

214 participants' socio-demographic background, opioid prescription was more frequent in

215 respondents with a lower education level. No significant gender or age difference was found

216 for opioid prescription.

11

Compared with no opioid prescription, Step III opioid prescription was significantly more frequent in unemployed respondents (18.0% versus 9.3% among those with executive jobs and 9.3 % for supervisors, p<0.001), respondents with anxiety (15.4% versus 13.1% among those without anxiety, p=0.02) and in those with metastases (45.0% versus 11.4% among those without metastasis, p<0.001). Furthermore, Step III opioid prescription was more frequent among respondents who underwent radiotherapy (17.1% versus 10.1% in those who did not, p<0.001)), and among those who had had inpatient PC (67.3% versus 13.4% in those who did not, p<0.001). For those who had had PC and were prescribed a Step III opioid, prescription occurred either in the same year as PC or the following year.

Moreover, Figure 1 shows significant differences between cancer sites and opioid prescription in survivors with CP. More specifically, Step III opioid prescription was most frequent for upper aerodigestive tract cancer (48.5%), followed by lung cancer (35.3%), and least frequent for melanoma (6.5%).

Factors associated with opioid prescription in cancer survivors with CP- Multivariable analyses

After adjustment for age, gender, and occupational status at the time of the survey, a multivariable multinomial logistic regression (Table 3) showed that being aged 65-74 years old at diagnosis, having a poorer physical QOL, having fewer comorbidities at the time of the survey, and having been prescribed fewer psychotropic drugs since diagnosis, were all negatively associated with Step II and Step III opioid prescription.

Factors positively associated with Step III opioid prescription included being unemployed five years after diagnosis, reporting depressive symptoms, having metastases, having undergone radiotherapy or chemotherapy, and having had inpatient PC since diagnosis. Moreover, several

12

240 factors were negatively associated with Step III opioid prescription including being aged 50-64,

241 65-74 or 75-82 years old and being a woman.

Discussion

243 Five years after cancer diagnosis, CP was reported by two thirds of respondents (63.5%). CP was

244 more frequent in younger patients and in women, and was associated with a multitude of other

245 symptoms such as anxiety, depression, fatigue and poorer physical and mental QOL. Among

246 those with CP, access to opioids - especially Step III opioids - was very limited and differed

247 according to patients' sociodemographic and medical characteristics. More specifically, men,

248 younger respondents, people with metastases, respondents with a poorer physical QOL, people

249 with depression, individuals who had other comorbidities, and those who underwent

250 chemotherapy or radiotherapy since diagnosis were the populations most likely to have been

251 prescribed a Step III opioid since diagnosis. Furthermore, we found that benefiting from

252 inpatient PC was associated with Step III opioid prescription.

253 To the best of our knowledge, this is the first study to explore CP prevalence, associated

254 symptoms and related treatment, and more specifically, to study the association between

255 opioid prescription in survivors with CP and inpatient PC, in a nationally representative sample

256 of survivors for a range of cancer sites. Prevalence and characteristics of pain five years after

257 diagnosis were measured using patient reported outcomes (PRO), since pain is subjective.

258 Moreover, the SNIIRAM data allowed us to collect objective and exhaustive data on drug

259 prescription since diagnosis, and therefore to overcome possible biases linked to self-reporting

260 in the study questionnaire.

261 Despite our several data sources, several limitations should be considered when interpreting

262 the results. First, pain for which opioids were prescribed was self-reported but not clinically

13

263 diagnosed. In addition, the SNIIRAM opioid-prescribing data are only an indirect indicator of

264 pain management history. It is therefore possible that the pain for which opioids were

265 prescribed was not cancer related, especially since SNIIRAM data do not provide information on

266 medical indications. In order to overcome this bias, we chose to limit our analyses to patients

267 with CP, assuming that when CP occurs in cancer patients, it may have a higher probability of

268 being related to cancer or cancer-related treatments than to other conditions. Another

269 limitation is that our survey did not include questions about patients' preferences regarding

270 opioids. The absence of these data did not allow us to assess the source of a possible under-

271 treatment rather related to the reluctance of patients to seek or use these drugs than a

272 problem of under-prescribing by doctors. Moreover, we did not account for opioids

273 prescription prior to the cancer diagnosis. However, a previous study showed that this

274 prescription , and in particular those of step III opioids, was very limited (54). Finally, we did not

275 consider hospital stays occurring in PC beds in acute care units, or admissions in PC inpatient

276 units. This may have led to an underestimation of PC access in this study.

277 Pain has been recognized as one of the most frequent cancer-related symptoms, with high

278 prevalence rates from diagnosis to death (1,2,6,55). A recent systematic review indicated

279 prevalence ranged from 40% to 66% depending on cancer stage and treatment (2). In our study,

280 at five years after cancer diagnosis, more than three-quarters of our study sample reported

281 pain of some type during the 15 days preceding the survey. Two-thirds of our study population

282 (63.5%) reported CP, ranging from 50.1% to 72.1% depending on the primo-cancer site. Higher

283 than those from existing studies (41,56), these prevalence rates - especially for CP – indicate

284 that pain remains an important issue in cancer survivors long after diagnosis. Furthermore,

285 these high CP prevalence rates raise questions about the true utility of various cancer, pain and

14

286 PC governmental programs and recommendations implemented in France over the last 15

287 years.

288 Previous studies have shown that chronic cancer pain could affect the global QOL of cancer

289 survivors, influencing fatigue, anxiety, depression and daily activities (14,15), and, our results

290 seem to reflect this. CP in our study was more frequent in respondents who reported more

291 comorbidities, poorer physical and mental QOL scores, more depression, more anxiety, more

292 fatigue, and among those who reported that their pain forced them to limit their daily

293 activities, confirming the weight and the major impact of CP on cancer survivors' overall QOL,

294 even years after diagnosis. These physical, psychological and social effects, together with the

295 spiritual impact, are bi-directional and cumulative, combining to give an overall pain profile

296 described as Total Pain (43), which requires global, multidisciplinary, holistic and patient-

297 centered management.

298 Our findings showed a significant relationship between CP and 1) prescription of

299 pharmacological options such as opioids and psychotropic drugs and, 2) the use of non-

300 pharmacological options such as acupuncture, hypnosis and osteopathy. These findings were

301 expected given the heavier burden of CP - with and without neuropathic pain - and the higher

302 prevalence of associated symptoms in these individuals. However, we observed that only 14.4%

303 of survivors with CP had been prescribed a Step III opioid since diagnosis (4.2% in the year of

304 the survey), which is lower than the percentage of other drugs prescribed (sometimes as a

305 substitute for Step III opioids), for example psychotropic drugs (73.2%). This under-prescription

306 of Step III opioids, despite the high rate of intense (25.2%) and moderate to intense pain (9.2%)

307 observed in our study, may have several explanations. Reluctance of health care providers to

308 prescribe, and of patients and their families to adhere to these opioids, as well as the fear of

15

309   dependence and other side effects are the barriers reported most often in the literature (57–

310   62). Moreover, we found that the presence of metastasis was associated with Step III opioid

311   prescription. This finding may partially explain the under-prescription of Step III opioids in our

312   study. It is possible that other drugs, such as adjuvant analgesics or weak opioids, may be

313   preferred to treat those with early-stage cancer, while Step III opioids may be prescribed more

314   frequently for advanced or terminal cancer patients (63,64). In addition, cancer-related

315   treatments, such as chemotherapy, would be one of the leading causes of iatrogenic pain and

316   painful neuropathy for example, which may partly explain why survivors who undergo

317   chemotherapy have been prescribed more opioids (step III in particular) (35).

318   Previous studies have shown that access to opioids may depend on patients' socio-

319   demographic and medical characteristics. For example, older patients and women are less likely

320   to be prescribed opioids and therefore more likely to be undertreated for their cancer-related

321   pain compared with younger patients and men (65–69). In line with these studies, age and

322   gender were significantly associated with opioid prescription, especially Step III opioids. The

323   probability of being prescribed Step III opioids decreased with age. This may seem logical since

324   older people tend to report cancer pain less often than younger people (70), something also

325   observed in our study. However, this may not reflect the possibility that older people may be

326   the most exposed to experience pain but prefer not to report it, leading to under-evaluation

327   and therefore under-treatment of that pain. Women in our study were more likely than men to

328   report CP, something reported in at least one other study (15) , but less likely to be prescribed

329   Step III opioids. The latter finding has already been reported in several studies and underlines

330   the problem of under-treatment of cancer-related pain in this population (65,69). Moreover,

331   our study showed a significant association between step III opioids prescription and access to

332   PC among survivors with chronic pain. Indeed, one previous study have shown that people who

16

333   have more invasive and metastatic cancers and who undergo more frequently adjuvant cancer

334   related-treatments such as chemotherapy and radiotherapy are the most likely to have an

335   inpatient PC access (71).

336   Although very limited in our study (1.6% in the overall study population and 1.9% in cancer

337   survivors with CP), inpatient PC care since diagnosis was positively associated with opioid

338   prescription (Step III in particular). Given the increasing number of cancer survivors in France

339   (i.e. 3 million in 2015), and the greater burden of the disease and its associated symptoms,

340   including pain right through the disease trajectory, ensuring the best QOL through multimodal

341   and multidisciplinary approaches remains a challenge for these survivors. Several studies have

342   shown that integrating PC early in the disease trajectory in conjunction with curative treatment

343   can enhance symptoms management, QOL and even survival (72,73). Our findings regarding the

344   prevalence of inpatient PC among survivors at five years following diagnosis, suggest that

345   common misconceptions about who should access this type of care and when, are still

346   widespread, and may deprive survivors of adequate relief of physical and psychological

347   symptoms (25).

348   Conclusion

349   Our study showed a high prevalence of CP in cancer survivors possibly due to an

350   undertreatment by Step III opioids. We found also that there is limited access to PC. It is

351   possible that we slightly underestimated this. Having said that, PC access was associated with

352   an increased likelihood of Step III opioid prescription in cancer survivors with CP. These findings

353   suggest the need to encourage greater Step III opioid prescription in this population, not just in

354   end-of-life situations. Finally, early access to PC for cancer survivors should be urgently

355   promoted to ensure access to Step III opioids for better CP management, irrespective of disease

356   stage.

Compliance with ethical standards

Conflict of interest

359   The authors declare that they have no conflict of interest.

Ethical approval

361   The study methodology was approved by the following national ethics commissions: the CCTIRS

362   (Consultative Committee on the Treatment of Health-related data, study registered under no.

363   11-143), the ISP (Institute of Public Health, study registered under no C11-63) and authorized

364   by the CNIL (French Commission on Individual Data Protection and Public Liberties, study

365   registered under no. 911290). With regard to personal responses and information provided,

366   confidentiality was ensured through data anonymization.

Informed consent

368   Informed consent was obtained from all individual participants included in the VICAN study.

Acknowledgments

370   The authors of this study thank the "Ligue contre le cancer" charity for providing a doctoral

371   fellowship to Asmaa Janah, and all the members of the VICAN study.

Author Contributions

373   All authors contributed to data analysis, drafting and revising the article, gave final approval of

374   the version to be published, and agree to be responsible for all aspects of the work.

Role of funder

376   This study was funded by The National Institute of Cancer (INCa), "Contrat de recherche et

377   développement no 05-2011."

18

References

1. Theobald DE. Cancer pain, fatigue, distress, and insomnia in cancer patients. Clin Cornerstone. 2004;6 Suppl 1D:S15-21.

2. van den Beuken-van Everdingen MHJ, Hochstenbach LMJ, Joosten EAJ, Tjan-Heijnen VCG, Janssen DJA. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage. 2016;51(6):1070-1090.e9.

3. Foley KM. How well is cancer pain treated? Palliat Med. 2011 Jul;25(5):398–401.

4. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin. 2011 Jun;61(3):157–82.

5. Sandgren A, Strang P. Palliative care needs in hospitalized cancer patients: a 5-year follow-up study. Support Care Cancer. 2018 Jan 1;26(1):181–6.

6. Schreier AM, Johnson LA, Vohra NA, Muzaffar M, Kyle B. Post-Treatment Symptoms of Pain, Anxiety, Sleep Disturbance, and Fatigue in Breast Cancer Survivors. Pain Manag Nurs Off J Am Soc Pain Manag Nurses. 2018 Dec 6;

7. Kokkonen K, Tasmuth T, Lehto JT, Kautiainen H, Elme A, Jääskeläinen A-S, et al. Cancer Patients' Symptom Burden and Health-related Quality of Life (HRQoL) at Tertiary Cancer Center from 2006 to 2013: A Cross-sectional Study. Anticancer Res. 2019 Jan;39(1):271–7.

8. Tan SY, Turner J, Kerin-Ayres K, Butler S, Deguchi C, Khatri S, et al. Health concerns of cancer survivors after primary anti-cancer treatment. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2019 Feb 1;

9. Mao JJ, Armstrong K, Bowman MA, Xie SX, Kadakia R, Farrar JT. Symptom Burden Among Cancer Survivors: Impact of Age and Comorbidity. J Am Board Fam Med. 2007 Jan 9;20(5):434–43.

10. Harrington CB, Hansen JA, Moskowitz M, Todd BL, Feuerstein M. It's not over when it's over: long-term symptoms in cancer survivors--a systematic review. Int J Psychiatry Med. 2010;40(2):163–81.

11. Berger AM, Visovsky C, Hertzog M, Holtz S, Loberiza FR. Usual and worst symptom severity and interference with function in breast cancer survivors. J Support Oncol. 2012 Jun;10(3):112–8.

12. Pachman DR, Barton DL, Swetz KM, Loprinzi CL. Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain. J Clin Oncol Off J Am Soc Clin Oncol. 2012 Oct 20;30(30):3687–96.

13. IASP. Chronic Pain has arrived in the ICD-11 - IASP [Internet]. 2019 [cited 2019 Oct 2]. Available from: https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=8340&navItemNumber=643

14. Mantyh PW. Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci. 2006 Oct;7(10):797–809.

15. Green CR, Hart-Johnson T, Loeffler DR. Cancer-related chronic pain: examining quality of life in diverse cancer survivors. Cancer. 2011 May 1;117(9):1994–2003.

19

413 16. Glare PA, Davies PS, Finlay E, Gulati A, Lemanne D, Moryl N, et al. Pain in Cancer Survivors. J Clin
414   Oncol. 2014 Jun 1;32(16):1739–47.

415 17. Merlin JS, Patel K, Thompson N, Kapo J, Keefe F, Liebschutz J, et al. Managing Chronic Pain in
416   Cancer Survivors Prescribed Long-Term Opioid Therapy: A National Survey of Ambulatory Palliative
417   Care Providers. J Pain Symptom Manage. 2019 Jan 1;57(1):20–7.

418 18. Jennings C, Cassel B, Fletcher D, Wang A, Archer KJ, Skoro N, et al. Response to pain management
419   among patients with active cancer, no evidence of disease, or chronic nonmalignant pain in an
420   outpatient palliative care clinic. J Palliat Med. 2014 Sep;17(9):990–4.

421 19. Bruera E, Hui D. Integrating supportive and palliative care in the trajectory of cancer: establishing
422   goals and models of care. J Clin Oncol Off J Am Soc Clin Oncol. 2010 Sep 1;28(25):4013–7.

423 20. Scotté F. The importance of supportive care in optimizing treatment outcomes of patients with
424   advanced prostate cancer. The Oncologist. 2012;17 Suppl 1:23–30.

425 21. WHO. Définition des Soins palliatifs. Organisation Mondiale de la Santé [Internet]. WHO. 2002
426   [cited 2019 Mar 13]. Available from: http://www.who.int/cancer/palliative/fr/

427 22. Cherny NI, Catane R, Kosmidis P. ESMO takes a stand on supportive and palliative care. Ann Oncol.
428   2003 Sep 1;14(9):1335–7.

429 23. INCa. Plan cancer 2014-2019. Institut National du Cancer. 2014.

430 24. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of Palliative Care
431   Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline
432   Update. J Clin Oncol Off J Am Soc Clin Oncol. 2017 Jan;35(1):96–112.

433 25. Hawley P. Barriers to Access to Palliative Care. Palliat Care [Internet]. 2017 Feb 20 [cited 2018 Jan
434   30];10. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5398324/

435 26. Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E, et al. Integration of oncology and
436   palliative care: a Lancet Oncology Commission. Lancet Oncol. 2018 Oct 17;

437 27. Bandieri E, Sichetti D, Romero M, Fanizza C, Belfiglio M, Buonaccorso L, et al. Impact of early
438   access to a palliative/supportive care intervention on pain management in patients with cancer.
439   Ann Oncol Off J Eur Soc Med Oncol. 2012 Aug;23(8):2016–20.

440 28. WHO. Cancer pain relief. World Health Organization. Geneva : Albany, NY: World Health
441   Organization ; WHO Publications Center USA [distributor]; 1986. 74 p.

442 29. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. The
443   Oncologist. 2004;9(5):571–91.

444 30. Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, et al. Management of Chronic
445   Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice
446   Guideline. J Clin Oncol. 2016 Jul 25;34(27):3325–45.

447 31. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment
448   in outpatients with metastatic cancer. N Engl J Med. 1994 Mar 3;330(9):592–6.

20

449   32.   Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F, ESMO Guidelines Working Group.
450   Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med
451   Oncol. 2012 Oct;23 Suppl 7:vii139-154.

452   33.   Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C, et al. Randomized Trial of Low-
453   Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. J Clin Oncol Off J Am Soc Clin
454   Oncol. 2016 10;34(5):436–42.

455   34.   Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health
456   Organization analgesic ladder? Cancer Control J Moffitt Cancer Cent. 2000 Apr;7(2):149–56.

457   35.   Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, et al. Management of cancer pain in adult
458   patients: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncol. 2018 Oct
459   1;29(Supplement_4):iv166–91.

460   36.   Hanks GW, Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al. Morphine and alternative
461   opioids in cancer pain: the EAPC recommendations. Br J Cancer. 2001 Mar 2;84(5):587–93.

462   37.   Cohen MZ, Easley MK, Ellis C, Hughes B, Ownby K, Rashad BG, et al. Cancer pain management and
463   the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage. 2003
464   Jun;25(6):519–27.

465   38.   van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J.
466   Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol Off
467   J Eur Soc Med Oncol. 2007 Sep;18(9):1437–49.

468   39.   Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A
469   review of published literature. Ann Oncol Off J Eur Soc Med Oncol. 2008 Dec;19(12):1985–91.

470   40.   Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-
471   European survey of prevalence, treatment, and patient attitudes. Ann Oncol Off J Eur Soc Med
472   Oncol. 2009 Aug;20(8):1420–33.

473   41.   INCa. Synthèse de l'enquête nationale 2010 sur la prise en charge de la douleur chez des patients
474   adultes atteints de cancer. [Internet]. 2012 [cited 2018 May 24]. Available from: www.e-
475   cancer.fr/content/download/63502/571325/file/ENQDOUL12.pdf

476   42.   Yates PM, Edwards HE, Nash RE, Walsh AM, Fentiman BJ, Skerman HM, et al. Barriers to Effective
477   Cancer Pain Management: A Survey of Hospitalized Cancer Patients in Australia. J Pain Symptom
478   Manage. 2002 May;23(5):393–405.

479   43.   Richmond C. Dame Cicely Saunders. BMJ. 2005 Jul 23;331(7510):238.

480   44.   Bouhnik A-D, Bendiane M-K, Cortaredona S, Sagaon Teyssier L, Rey D, Berenger C, et al. The labour
481   market, psychosocial outcomes and health conditions in cancer survivors: protocol for a
482   nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey). BMJ Open.
483   2015 Mar 24;5(3):e005971.

484   45.   Haute Autorité de Santé (HAS). Douleur chronique : reconnaître le syndrome douloureux
485   chronique, l'évaluer et orienter le patient. Consensus formalisé. RECOMMANDATIONS
486   PROFESSIONNELLES. 2008 p. 754–774.

487 46. Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain
488   syndromes associated with nervous or somatic lesions and development of a new neuropathic
489   pain diagnostic questionnaire (DN4). Pain. 2005 Mar;114(1–2):29–36.

490 47. WHO Collaborating Centre for Drug Statistics Methodology. About the ATC/DDD system.
491   Norwegian Institute of Public Health. 2007. [Internet]. [cited 2016 Apr 17]. Available from:
492   https://www.whocc.no/atc_ddd_index/?code=N02A&showdescription=yes

493 48. Burdine JN, Felix MR, Abel AL, Wiltraut CJ, Musselman YJ. The SF-12 as a population health
494   measure: an exploratory examination of potential for application. Health Serv Res. 2000
495   Oct;35(4):885–904.

496 49. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983
497   Jun;67(6):361–70.

498 50. Groenvold M, Klee MC, Sprangers MA, Aaronson NK. Validation of the EORTC QLQ-C30 quality of
499   life questionnaire through combined qualitative and quantitative assessment of patient-observer
500   agreement. J Clin Epidemiol. 1997 Apr;50(4):441–50.

501 51. Storey DJ, Waters RA, Hibberd CJ, Rush RW, Cargill AT, Wall LR, et al. Clinically relevant fatigue in
502   cancer outpatients: the Edinburgh Cancer Centre symptom study. Ann Oncol Off J Eur Soc Med
503   Oncol. 2007 Nov;18(11):1861–9.

504 52. Cortaredona S, Pambrun E, Verdoux H, Verger P. Comparison of pharmacy-based and diagnosis-
505   based comorbidity measures from medical administrative data. Pharmacoepidemiol Drug Saf.
506   2017 Apr;26(4):402–11.

507 53. INCa. La vie cinq ans après un diagnostic de cancer. 2018 Jun p. 364.

508 54. Janah A, Bouhnik A-D, Cortaredona S, Mancini J, Bousquet PJ, Peretti-Watel P, et al. Opioid
509   analgesics prescription in people with and without cancer in France. J Opioid Manag. 2018 Sep
510   5;14(4):245–56.

511 55. Teunissen SCCM, Wesker W, Kruitwagen C, de Haes HCJM, Voest EE, de Graeff A. Symptom
512   prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007
513   Jul;34(1):94–104.

514 56. Bouhassira D, Luporsi E, Krakowski I. Prevalence and incidence of chronic pain with or without
515   neuropathic characteristics in patients with cancer. Pain. 2017;158(6):1118–25.

516 57. Chow R, Saunders K, Burke H, Belanger A, Chow E. Needs assessment of primary care physicians in
517   the management of chronic pain in cancer survivors. Support Care Cancer. 2017 Nov
518   1;25(11):3505–14.

519 58. Gunnarsdottir S, Donovan HS, Serlin RC, Voge C, Ward S. Patient-related barriers to pain
520   management: the Barriers Questionnaire II (BQ-II). Pain. 2002 Oct;99(3):385–96.

521 59. Sun V, Borneman T, Piper B, Koczywas M, Ferrell B. Barriers to pain assessment and management
522   in cancer survivorship. J Cancer Surviv Res Pract. 2008 Mar;2(1):65–71.

523 60. Jacobsen R, Møldrup C, Christrup L, Sjøgren P. Patient-related barriers to cancer pain
524   management: a systematic exploratory review. Scand J Caring Sci. 2009 Mar;23(1):190–208.

525 61. Oldenmenger WH, Sillevis Smitt PAE, van Dooren S, Stoter G, van der Rijt CCD. A systematic review
526   on barriers hindering adequate cancer pain management and interventions to reduce them: a
527   critical appraisal. Eur J Cancer Oxf Engl 1990. 2009 May;45(8):1370–80.

528 62. Xia Z. Cancer pain management in China: current status and practice implications based on the
529   ACHEON survey [Internet]. Journal of Pain Research. 2017 [cited 2019 Apr 30]. Available from:
530   https://www.dovepress.com/cancer-pain-management-in-china-current-status-and-practice-
531   implicatio-peer-reviewed-fulltext-article-JPR

532 63. Ziegler L, Mulvey M, Blenkinsopp A, Petty D, Bennett MI. Opioid prescribing for patients with
533   cancer in the last year of life: a longitudinal population cohort study. PAIN. 2016
534   Nov;157(11):2445–51.

535 64. Jarlbaek L, Hansen DG, Bruera E, Andersen M. Frequency of opioid use in a population of cancer
536   patients during the trajectory of the disease. Clin Oncol R Coll Radiol G B. 2010 Apr;22(3):199–207.

537 65. Moryl N, Dave V, Glare P, Bokhari A, Malhotra VT, Gulati A, et al. Patient-Reported Outcomes and
538   Opioid Use by Outpatient Cancer Patients. J Pain Off J Am Pain Soc. 2018 Mar;19(3):278–90.

539 66. McNeill JA, Sherwood GD, Starck PL. The hidden error of mismanaged pain: a systems approach. J
540   Pain Symptom Manage. 2004 Jul;28(1):47–58.

541 67. Di Maio M, Gridelli C, Gallo C, Manzione L, Brancaccio L, Barbera S, et al. Prevalence and
542   management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer. 2004
543   Jun 14;90(12):2288–96.

544 68. Stein KD, Alcaraz KI, Kamson C, Fallon EA, Smith TG. Sociodemographic inequalities in barriers to
545   cancer pain management: a report from the American Cancer Society's Study of Cancer Survivors-II
546   (SCS-II). Psychooncology. 2016 Oct;25(10):1212–21.

547 69. Chou P-L, Fang S-Y, Sun J-L, Rau K-M, Lee B-O. Gender Difference in Cancer Patients' Adherence to
548   Analgesics and Related Outcomes of Pain Management. Cancer Nurs. 2018 Dec;41(6):E11–8.

549 70. INCa. « La vie deux ans après un diagnostic de cancer - De l'annonce à l'après cancer ». collection
550   Études et enquêtes; 2014.

551 71. Janah A, Gauthier LR, Morin L, Bousquet PJ, Le Bihan C, Tuppin P, et al. Access to palliative care for
552   cancer patients between diagnosis and death: a national cohort study. Clin Epidemiol.
553   2019;11:443–55.

554 72. Zimmermann C, Swami N, Krzyzanowska M, Hannon B, Leighl N, Oza A, et al. Early palliative care
555   for patients with advanced cancer: a cluster-randomised controlled trial. Lancet Lond Engl. 2014
556   May 17;383(9930):1721–30.

557 73. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care
558   for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733–42.

23

Table 1. Prevalence of chronic pain according to cancer survivor (5-year) study population

characteristics (National VICAN survey, N = 4,093)

	Total	No chronic pain [d]	Chronic pain, five years after diagnosis [d,f]
All	100%	36.5%	63.5%
	Column (%)	Row (%)	
Socio-demographic characteristics			
Age (years) [a]			
18-49	39.5	33.0	67.0 ***
50-64	33.0	35.9	64.1
65-74	21.2	42.1	57.9
75-82	6.3	42.9	57.1
Gender			
Men	37.4	45.8	54.2 ***
Women	62.6	30.9	69.1
Education level [b]			
< High school diploma	50.5	34.4	65.6 *
≥ High school diploma	49.5	38.6	61.4
Occupational status [b]			
Tradesperson/Employee	23.2	32.6	67.4 *
Supervisor	18.6	40.0	60.0
Unemployed	58.2	36.8	63.2

Medical characteristics			
Cancer site			
Breast	41.4	27.9	72.1 ***
Lung	3.6	31.2	68.8
Rectum/colon	10.0	43.7	56.3
Prostate	16.3	48.9	51.1
Aero-digestive tract	4.6	34.1	65.9
Bladder	3.2	49.9	50.1
Kidney	3.6	38.9	61.1
Thyroid	5.2	36.5	63.5
Non-Hodgkin lymphoma	3.8	43.8	56.2
Melanoma	4.9	44.6	55.4
Cervical	2.2	34.0	66.0
Endometrial	1.2	35.6	64.4
Neuropathic pain [b]			
No	26.5	100	0 ***
Negative screening (DN4)	47.3	17.0	83.0
Positive screening (DN4)	26.2	7.2	92.8
Limited daily activity due to pain [b, e]			
Disagree	60.1	49.9	50.1 ***
Agree	39.9	16.7	83.3
Depression [b]			
No	82.8	39.4	60.6 ***

Yes (doubtful or certain)	17.2	21.9	78.1
Anxiety [b]			
No	53.1	45.8	54.2 ***
Yes (doubtful or certain)	46.9	25.8	74.2
Fatigue (clinically significant score) [b]			
No	51.5	49.2	51.8 ***
Yes	48.5	22.9	77.1
Physical quality of life [b]			
Mean [Standard Deviation]	45.3 (9.9)	49.9 (8.6)	42.6 (9.6) ***
Mental quality of life [b]			
Mean [Standard Deviation]	45.2 (10.5)	48.3 (9.6)	43.4 (10.5) ***
Comorbidities [b]			
Mean [Standard Deviation]	0.7 (0.5)	0.6 (0.5)	0.7 (0.5) ***
Radiotherapy [c]			
No	42.5	41.8	58.2 ***
Yes	57.5	32.6	67.4
Chemotherapy [c]			
No	54.9	40.9	59.1 ***
Yes	45.1	31.1	48.9
Inpatient PC [c]			
No	98.4	36.7	63.3 ns
Yes	1.6	25.5	74.5
Step II opioid prescription [c]			

No	24.8	45.0	55.0 ***
Yes	75.2	33.7	66.3
Step III opioid prescription [c]			
No	87.9	38.1	61.9 ***
Yes	12.1	24.5	75.5
Opioid prescription [c]			
No opioid prescription	24.4	45.3	54.7 ***
Step II opioid prescription	63.5	35.4	64.6
Step III opioid prescription	12.1	24.5	75.5
Opioid prescription [b]			
No opioid prescription	73.9	38.7	61.3 ***
Step II opioid prescription	22.9	32.0	68.0
Step III opioid prescription	3.2	17.1	82.9
Psychotropic drug prescription [c]			
No	31.4	45.9	54.1 ***
Yes	68.6	32.2	67.8
Hypnosis [c]			
No	97.0	37.1	62.9 **
Yes	3.0	20.8	79.2
Acupuncture [c]			
No	89.7	38.3	61.7 ***
Yes	10.3	21.3	78.7
Osteopathy [c]			

No	73.4	41.1	58.9 ***
Yes	26.6	23.8	76.2

561   [a] At diagnosis
562   [b] Five years after diagnosis
563   [c] Since diagnosis (i.e., between diagnosis and the year of the survey) .
564   [d] The modalities of the two questions regarding pain prevalence and duration were merged to construct a single variable coded
565   "**No Chronic pain**" which combined "No pain of any type in the previous 15 days" with "pain of some type in the previous 15
566   days but experienced for <3 months", and "**Chronic pain**" which combined pain experienced for "≥ 3 months but < 6 months",
567   and "≥ 6 months"
568   [e] For the question on the impact of pain on daily activities, the items "mostly agree" and completely agree" were merged into
569   the category "agree", and the categories, "neither agree nor disagree", "mostly disagree" and "completely disagree" were
570   merged into the category "disagree".
571   [f] ***, **, *, significant at p < 0,001, p < 0,01, p < 0,05 (X^2 test or Student's t test)

572   Table 2. Variables associated with opioid prescription among cancer survivors with chronic pain

573   (National VICAN survey, N = 2,578)

	Total	No prescription [c] (ref.)	Step II opioid prescription [c,e]	Step III opioid prescription [c,e]
	Column (%)	Row (%)		
All (%, row)	100	21.0	64.6	14.4
<u>**Socio-demographic characteristics**</u>				
Age (years) [a]				
18-49	41.7	19.3	66.3 ns	14.4 ns
50-64	33.4	20.8	62.6	16.6
65-74	19.3	25.5	63.4	11.1
75-82	5.6	18.4	68.0	13.6
Gender				
Men	31.9	21.3	62.1 ns	16.6 ns
Women	68.1	20.8	65.8	13.4
Education level [b]				
< High-school diploma	52.2	18.0	65.5 **	16.5 ***
≥ High-school diploma	47.8	24.2	63.7	12.1
Occupational status [b]				
Tradesperson/Employee	24.6	20.7	70.0 ns	9.3 ***

Supervisor	17.6	21.8	68.9	9.3
Unemployed	57.8	20.8	61.2	18.0
Medical characteristics				
Neuropathic pain [b]				
Negative screening (DN4)	61.8	24.0	63.3 ***	12.7 ***
Positive screening (DN4)	38.2	16.2	66.7	17.1
Experienced pain intensity [b, d]				
Intense	25.2	13.0	63.9 **	23.1 ***
Neither intense nor moderate	9.2	24.4	57.6	18.0
Moderate	65.6	23.3	66.1	10.6
Limited daily activity due to pain [b]				
Disagree	47.5	26.0	65.6 ***	8.4 ***
Agree	52.5	16.6	63.8	19.6
Depression [b]				
No	78.9	23.1	65.3 **	11.6 ***
Yes (doubtful or certain)	21.1	12.8	62.7	24.5
Anxiety [b]				
No	45.3	23.2	63.7 ns	13.1*
Yes (doubtful or certain)	54.7	19.1	65.5	15.4
Fatigue (clinically significant score) [b]				

No	41.2	26.5	63.9 ***	9.6 ***
Yes	58.8	17.2	65.1	17.7
Physical quality of life [b]				
Mean [Standard Deviation]	42.6 (9.6)	45.5 [8.6]	42.9 [9.3] ***	37.3 [10.9] ***
Mental quality of life [b]				
Mean [Standard Deviation]	43.4 (10.5)	45.1 [9.6]	43.4 [10.6] **	40.8 [11.3] ***
Comorbidities [b]				
Mean [Standard Deviation]	0.7 (0.5)	0.5 [0.4]	0.7 [0.5] ***	1.0 [0.6] ***
Metastases [c]				
No	91.1	22.2	66.4 ns	11.4 ***
Yes	8.9	9.1	45.9	45.0
Radiotherapy [c]				
No	38.9	22.3	67.6 ns	10.1 ***
Yes	61.1	20.2	62.7	17.1
Chemotherapy [c]				
No	51.1	24.6	67.1 *	8.3 ***
Yes	48.9	17.2	62.1	20.7
Inpatient palliative care [c]				
No	98.1	21.3	65.3 ns	13.4 ***
Yes	1.9	3.5	29.2	67.3
Step II opioids prescription [c]				
No	21.5	97.6	0 ***	2.4 ***
Yes	78.5	0	82.3	17.7

Psychotropic drug prescription [c]				
No	26.8	35.8	59.6 ***	4.6 ***
Yes	73.2	15.6	66.4	18.0

574   [a] At diagnosis

575   [b] Five years after diagnosis

576   [c] Since diagnosis (between diagnosis and the year of the survey)

577   [d] For pain intensity variable, the categories "extremely intense", "very intense", "quite intense", were merged into the category

578   "intense", and the categories "quite moderate", "very moderate" and "extremely moderate" were merged into the category

579   "moderate".

580   [e] ***, **, *, significant at $p < 0,001$, $p < 0,01$, $p < 0,05$ (chi-square test or Student's t test)

Figure 1. Opioid prescription among cancer survivors with chronic pain according to cancer site.

(National VICAN survey, N = 2,578) (Row, %) (Chi-square test, P<0.001)

583   Table 3. Factors associated with opioid prescription among cancer survivors with chronic pain

584   using multinomial logistic regression (National VICAN survey, N=2,548)

	Step II opioid prescription [c, d]	Step III opioid prescription [c, d]
	(Adjusted Relative Risk Ratio [95% CI]) [d,e,f]	
Socio-demographic characteristics		
Age (years) [a] (ref. 18-49 years)		
50-64	0.81 [0.61,1.07]	0.64 [0.43,0.94] *
65-74	0.46 [0.32,0.67] ***	0.25 [0.15,0.42] ***
75-82	0.71 [0.40,1.24]	0.34 [0.16, 0.75] **
Gender (ref. Men)		
Women	0.80 [0.63,1.03]	0.48 [0.35,0.68] ***
Occupational status [b] (ref. Tradesperson/Employee)		
Supervisor	0.97 [0.70,1.33]	1.04 [0.63,1.71]
Unemployed	0.87 [0.64,1.19]	1.70 [1.10,2.64] *
Medical characteristics		
Physical health [b]	0.98 [0.97, 0.99] **	0.95 [0.93,0.96] ***
Depression [b] (ref. No)		
Yes (doubtful or certain)	1.31 [0.97,1.77]	1.57 [1.08,2.28] *
Comorbidities [b]	2.78 [2.10,3.67] ***	5.20 [3.67,7.38] ***
Metastases [c] (ref. No)		

Yes	1.60 [0.96,2.65]	2.52 [1.44,4.40]**
Radiotherapy [c] (ref. No)		
Yes	0.97 [0.78,1.21]	1.92 [1.40,2.65] ***
Chemotherapy [c] (ref. No)		
Yes	1.08 [0.86,1.36]	1.99 [1.43,2.76] ***
Inpatient palliative care [c] (ref. No)		
Yes	1.23 [0.27,5.69]	5.33 [1.15,24.58]*
Psychotropic drug prescription [c] (ref. No)		
Yes	2.03 [1.63,2.54]***	5.60 [3.70,8.48] ***

[a] At diagnosis

[b] Five years after diagnosis

[c] Since diagnosis (i.e., between diagnosis and the year of the survey)

[d] The two multivariate logistic models separately compare (1) individuals prescribed at least one Step II opioid over the period from diagnosis to the survey year with individuals who received no opioid in the same period, and (2) individuals prescribed at least one Step III opioid over the period from diagnosis to the survey year with individuals who received no opioid in the same period.

[e] All the variables presented in Table 2 were tested. Only those significant at a threshold of 20% were used to perform the multivariate logistic regressions. The latter was selected using a forward stepwise selection procedure (probability threshold = 20%, probability of staying in the model =5%).

[f] ***, **, *: significant at p < 0.001, p < 0.01, and p < 0.05